Literature DB >> 11108827

Adenosine A1 receptor blockade reverses dysmotility induced by ischemia-reperfusion in rat colon.

M Kadowaki1, K Tokita, Y Nagakura, M Takeda, K Hanaoka, M Tomoi.   

Abstract

This study was designed to assess whether adenosine A1 receptor antagonists [(R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl) acryloyl]-piperidin-2-yl acetic acid (FK352) and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX)] reverse dysmotility induced by ischemia-reperfusion in the rat colon. The gene of adenosine A1 receptor was expressed in the colon. Clamping (30 min) of the colonic marginal vessels was followed by reperfusion, and the propulsive colonic motility was evaluated. Propulsion was significantly slowed by ischemia-reperfusion, while FK352 and DPCPX abolished this delay. In contrast, the non-selective adenosine receptor antagonist, 8-phenyltheophylline, failed to affect the dysmotility. Thus, adenosine A1 receptor antagonists have potent therapeutic potential against ischemia-reperfusion-induced dysmotility in the colon.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11108827     DOI: 10.1016/s0014-2999(00)00867-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Pretreatment with adenosine and adenosine A1 receptor agonist protects against intestinal ischemia-reperfusion injury in rat.

Authors:  V Haktan Ozacmak; Hale Sayan
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

2.  Purinergic receptors and synaptic transmission in enteric neurons.

Authors:  Jianhua Ren; Paul P Bertrand
Journal:  Purinergic Signal       Date:  2007-12-08       Impact factor: 3.765

3.  Purinergic mechanisms in the control of gastrointestinal motility.

Authors:  J C Bornstein
Journal:  Purinergic Signal       Date:  2007-10-06       Impact factor: 3.765

4.  Adenosine negatively regulates duodenal motility in mice: role of A(1) and A(2A) receptors.

Authors:  M G Zizzo; M Mastropaolo; L Lentini; F Mulè; R Serio
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.